China Consumer Prices Forecast Inflation

Published 16-JAN-2017 12:18 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Inflationary pressure could increase later this year, but light is at the end of the tunnel for heavy industry prices in China. That’s according to new data out today from China’s leading business school, Cheung Kong Graduate School of Business (CKGSB).

The CKGSB Business Conditions Index (BCI), which surveys executives at leading Chinese companies and asks them to forecast business conditions over the next six months, registered 61.4 in December, up from 60.8 in November, showing that for CKGSB’s sample of relatively successful businesses, optimism about future prospects is continuing to grow.

Meanwhile, the consumer prices index rose in December, from 61.1 to 64.9, while the producer prices index broke through the threshold of 50, registering 52.4. China’s National Bureau of Statistics is due to release its monthly report on the Consumer Price Index (CPI), as well as the Producer Prices for the industrial sector, later on Tuesday January 10.

Commenting on the results, CKGSB Professor of Economics Li Wei said, “The accepted view is that inflationary pressure will be minimal this year, but our consumer prices data shows that expectations of inflation ahead are taking shape. Meanwhile, an important shift has taken place this month, with the producer prices data finally rising above the confidence threshold of 50. The last time the index registered such positive prospects was in October 2014. This is in keeping with brighter prospects for heavy industry prices.”

The CKGSB BCI comprises four sub-indices for corporate sales, corporate profits, corporate financing environment and inventory levels, all measuring future prospects except for the financing environment, which measures the current situation.

Launched in June 2011 under the direction of CKGSB Economics Professor Li Wei, the CKGSB Case Center and the Center for Economic Research initiated a project to gauge the business sentiment of executives – the majority of whom are current or former students at CKGSB – about the macro-economic environment in China.

About CKGSB

Established in November 2002, Cheung Kong Graduate School of Business is China’s first faculty-governed and independent business school. CKGSB boasts more than 40 full-time professors, who have earned their PhDs or held tenured faculty positions at leading schools such as Harvard, Wharton and Stanford. Their research has provided the basis for nearly 400 case studies of both China-specific and global issues. More than half of CKGSB’s 10,000+ alumni are at the CEO or Chairman level and, together, their companies accounted for one sixth of China’s GDP in 2015.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X